Trial Profile
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 01 Dec 2023 Results of a pooled analysis assessing Joint safety events from 3 phase 3 clinical studies (NCT02697773, NCT02709486 and NCT02528188) published in the Osteoarthritis and Cartilage
- 01 Apr 2023 Results assessing the relationships among treatment, pain, and physical function from 2 published randomized clinical (NCT02697773 and NCT02709486) trials of osteoarthritis patients who received tanezumab or a placebo, published in the Clinical Journal of Pain.
- 09 Jan 2023 Pooled analysis from 2 randomized Phase 3 clinical trials (NCT02697773 and NCT02709486) assessing patient-based variables that predicted responses to treatments published in the Clinical Pharmacology and Therapeutics